Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study
Author:
Funder
ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://link.springer.com/article/10.1007/s12185-017-2238-9/fulltext.html
Reference25 articles.
1. Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.
2. Kantar Health. Treatment Architecture: Japan-Leukemia, Chronic Myelogenous. CancerMPact® Japan, V1.4; 2013 (October 2014).
3. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1126 (abstract).
4. Hochhaus A, Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, For the IRIS Investigators, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–61 (erratum, Leukemia. 2010; 24:1102).
5. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–68.
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis;Expert Opinion on Drug Safety;2023-10-18
2. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis;Cancers;2023-08-31
3. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022;International Journal of Clinical Oncology;2023-06-29
4. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists;International Journal of Clinical Oncology;2023-03-05
5. Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients;British Journal of Clinical Pharmacology;2023-01-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3